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Abstract: Hydrothermally converted coralline hydroxyapatite (HAp) particles loaded with 
medically active substances were used to develop polylactic acid (PLA) thin film 
composites for slow drug delivery systems. The effects of HAp particles within PLA 
matrix on the gentamicin (GM) release and release kinetics were studied. The gentamicin 
release kinetics seemed to follow Power law Korsmeyer Peppas model with mainly 
diffusional process with a number of different drug transport mechanisms. Statistical 
analysis shows very significant difference on the release of gentamicin between GM 
containing PLA (PLAGM) and GM containing HAp microspheres within PLA matrix 
(PLAHApGM) devices, which PLAHApGM displays lower release rates. The use of HAp 
particles improved drug stabilization and higher drug encapsulation efficiency of the 
carrier. HAp is also the source of Ca2+ for the regeneration and repair of diseased bone 
tissue. The release profiles, exhibited a steady state release rate with significant 
antimicrobial activity against Staphylococcus aureus (S. aureus) (SH1000) even at high 
concentration of bacteria. The devices also indicated significant ability to control the 
growth of bacterial even after four weeks of drug release. Clinical release profiles can be 
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easily tuned from drug-HAp physicochemical interactions and degradation kinetics of 
polymer matrix. The developed systems could be applied to prevent microbial adhesion to 
medical implant surfaces and to treat infections mainly caused by S. aureus in surgery. 
Keywords: drug release; thin film composites; coral; hydroxyapatite; microbial adhesion; 
S. aureus  
 
1. Introduction 
Current increases in the ageing population and increased longevity due to medical advances in 
many developed countries has led to a rise in the number of musculoskeletal disorders (MSDs). The 
number of medications to prevent and treat these diseases has also expanded in recent times due to 
scientific advances. The development of new drugs and active substances allows treatment of some of 
these diseases in very early stages. The key issue that has been explored widely in recent times with 
regards to these treatments is the ability to direct drugs to specific organs and musculo-skeletal sites. 
Most importantly, these treatments are designed to be able to effect locally when required. They are 
required to control the release rate of the drugs, in order to maintain a desired drug concentration levels 
without reaching to a toxic level or dropping below a minimum effective level. For these reasons, a 
major effort has been directed on the development of biodegradable materials that are capable of 
releasing drugs by reproducible and predictable kinetics [1,2]. 
Drug delivery technology presents an interesting interdisciplinary challenge for pharmaceutical, 
chemical engineering, biomaterials and medical communities [3]. In general, a biomaterial that will act 
as a drug carrier must have the ability to incorporate a drug, to retain it in a specific site, and to deliver 
it progressively with time to the surrounding tissues. Furthermore, it would be advantageous if the 
material is injectable or alternatively coatable on an implant and most importantly biodegradable.  
It has been reported that calcium phosphate bone substitutes derived from mixed hydroxyapatite and 
β tricalcium phosphate (β-TCP) are the most promising materials for bone drug delivery systems [4]. 
During the last decade there have been several studies on both commercial and experimental calcium 
phosphate drug carriers [1]. Major attention has been focused on the delivery of antibiotics, due to 
their wide areas of applications as prevention against infection during surgical interventions or in 
general in the treatment of bone infections.  
Ceramics and other materials have been proposed in the past, but it is difficult to form an 
appropriate shape with adequate micro porosity in order to be fitted into any type and size of bone 
defect. The treatment of bone infection remains difficult because of problems with local penetration of 
systemically administered antibiotic. Furthermore, bacteria adhere to bone matrix and orthopaedic 
implants, eluding host defences by developing a biofilm or acquiring a very slow metabolic rate [5]. 
Effective treatment against infection may be possible by killing the bacteria during the early stages of 
colonization, followed by the continuous long time steady state delivery of appropriate amounts  
of antibiotics.  
Recently it has been demonstrated that marine shells with specific microspherical design offer 
desired functions for the delivery of Bisphosphonate (paminodrate) and antibiotic (Gentamicin). This 
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has been possible by virtue of its unique structure and architecture of the foraminifera shells which are 
extraordinarily difficult to manufacture with the current know-how [6].  
Biodegradable polymer films loaded with gentamicin have been developed to serve as “coatings” 
for fracture fixation devices and prevent implant-associated infections [7]. The use of biodegradable 
polymer films is advantageous due to its propensity to uptake and release antibiotics, as a consequence 
of its degradability. Although their drug release rates are high, they could be tailored to form 
biocomposites with different biodegradability rates by incorporating other materials. Biodegradable 
polymer-bioceramic composites would be ideal in this endeavour because of the bioactive nature of 
ceramic materials which promotes tissue growth. Incorporation of bioceramics in these films will 
improve not only controlled drug release but also bioactivity and tissue regeneration, especially in 
orthopaedic and maxillofacial applications. Sampath et al. [8] demonstrated that PLA microcapsules 
could release more than 80% of loaded gentamicin sulphate within 3 weeks for the treatment of 
osteomyelitis. Drug release time and the shape of the release systems would limit their applications 
especially for prolonged release. Bioerodable, Polyanhydride-Gentamicin beads were used in vivo 
study for the treatment of Osteomyelitis by surgical debridement by Nelson et al. [9]. They reported to 
have eradicated osteomyelitis by 93% after 4 weeks of implantation for 20% gentamicin loaded beads. 
However most of these past published investigations have shown that antibiotics have been ototoxic 
and nephrotoxic at high dosages. For most controlled release systems, the loaded dosages are usually 
high, and therefore the systemic exposure of antibiotic in blood and urine is the major safety concern. 
Moreover none of these reported systems contain the key minerals like Ca2+ to support bone repair and 
regeneration. In this research, converted coralline hydroxyapatite (HAp) particles loaded with 
medically active drugs and substances were used to develop polylactic acid (PLA) thin film 
composites for slow drug delivery systems. 
2. Results and Discussion 
2.1. Results  
2.1.1. Susceptibility Testing and Drug Encapsulation Efficiency (DEE) 
The Minimum Inhibitory Concentration of Gentamicin against S. aureus (SH1000) was found to be 
1 μg/mL. DEE was determined to be 94.2% and 98.9% for PLAGM and PLAHApGM films respectively. 
2.1.2. Drug Loading to HAp 
Scanning electron microscopy (SEM) was used to analyze drug loading into HAp particles.  
Figure 1 shows images of HAp before and after drug loading. It was evident that converted coral 
particles are coated with drug into micro, meso and nanopores as drug solution could easily penetrate 
into these pores. On the other hand the surface of HAp before loading reveals thin platelets of HAp 
crystals while after loading the surface looks relative smooth due to drug coating. 
Mar. Drugs 2015, 13 669 
 
 
 
Figure 1. (a) Hydrothermal converted coralline HAp; (b) Gentamicin coated coralline HAp. 
2.1.3. Tensile Strength and Elongation at Break of Composites 
Figure 2 represents mechanical properties of PLAHAp composites at different HAp compositions. 
Tensile strength decreases as HAp content increases due to poor interfacial bond between PLA and 
Hap particles. On the other hand elongation increase as HAp contents increases suggesting the increase 
of composite flexibility due to introduction of voids within the matrix [10].  
 
Figure 2. Mechanical properties of PLAHAp composites. 
2.1.4. In-Vitro Gentamicin Release 
The central objective of a delivery system is to release therapeutics at the desired anatomical site 
and to maintain the drug concentration within a therapeutic band for a desired duration. Prolonged 
release of gentamicin from PLA thin film composites was studied and presented in Figure 3. 
Generally, the release of drug from biodegradable systems is rather complex phenomenon which can 
be governed by diffusion, dissolution, erosion and most often by a combination of these mechanisms. 
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That is the reason why an adequate empirical or semi-empirical model that incorporates most of the 
release governing factors is required for the assessment of the release kinetics.  
 
Figure 3. Fractional cumulative release of gentamicin from polylactic acid (PLA) thin film 
composite in phosphate buffered saline (PBS) solution (pH 7.4, 37 °C and 100 rpm), for 
eight weeks. Error bars are mean standard deviation (SD) of triplicate experimental data.  
2.1.4.1. Release Kinetics—Model Dependent Method 
The release kinetic study was assessed by model dependent method. Based on number of  
kinetic models available in literature, which described the overall release of drug from the dosage 
forms, were carefully selected and used to fit the release data [11–14]. Finally, data were fitted to 
seven different models: Zero order, 1st Order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas and 
Reciprocal powered time.  
The correlation coefficients (r2) indicate that drug release kinetic of PLAGM and PLAHApGM 
fitted with the power law model described by Korsmeyer-Peppas (Table 1). If this semi-empirical 
equation doesn’t allow for the determination of all of the mechanisms involved in the release, it is still 
possible to determine the mechanisms of transport by considering two borderline cases, which 
correspond to distinct physical realities (when n = 0.5 and n = 1). The n coefficient obtained for 
PLAGM (n < 0.5) indicates that the release mechanism was mainly controlled by diffusion while the 
value obtained for PLAHApGM (n > 1) is characteristic of number of mixed transport mechanisms 
including diffusion, possibly super case II kinetics as well as a release due to damage to the composite 
surface through dissolution. 
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Table 1. Modelled dissolution characteristics of the mean dissolution profile. 
Model Mathematical Expression  PLAGM PLAHApGM 
Zero order 𝐹 = 𝑄0 + 𝑘0𝑡 
𝑟2 
k0 
0.440 
0.125 
0.937 
0.070 
First order 𝐿𝑛(1 − 𝐹) = −𝑘𝑡 
𝑟2 
k 
0.866 
0.226 
0.874 
0.098 
Higuchi 𝐹 = 𝑎𝑡1/2 + 𝑏 
𝑟2 
a 
0.959 
0.273 
0.803 
0.214 
Hixson- Crowell 1 −  (1 − 𝐹)1/3 = 𝑘𝑡 
𝑟2 
k 
0.758 
0.060 
0.898 
0.029 
Korsmeyer-Peppas 𝐹 = 𝑘𝑡𝑛 
𝑟2 
n 
0.992 
0.282 
0.962 
1.315 
Baker Lonsdale 
3
2
[1 − (1 − 𝐹)2/3] × 𝐹 = 𝑘𝑡 
𝑟2 
k 
0.945 
0.107 
0.727 
0.038 
Reciprocal powered time (
1
𝐹
− 1) =
𝑚
𝑡𝑏
 
𝑟2 
b 
m 
0.971 
0.744 
1.524 
0.835 
1.037 
17.190 
F = fraction of drug released up to time t, r2 = Square correlation coefficient, Qo, k0, k, a, b, n, m and b are 
parameters of the models.  
2.1.4.2. Release Kinetics—Comparison of Drug Release Profiles 
PLAGM and PLAHApGM dissolution profiles were compared using statistical difference factors, 
difference factor (f1), and similarity factor (f2) (Table 2). The test indicates that there is a significant 
statistical difference between the two kinetic profiles. This difference is confirmed by the release  
half-life (t50%) obtained for each material loaded with gentamicin. Thus, the release half-life of 
PLAGM is obtained around 14 days while 124 days are necessary for PLAHApGM.  
Table 2. Modelled dissolution characteristics and difference and similarity factors of PLA 
film and PLAHAp composites loaded with gentamicin. 
 PLAGM PLAHApGM 
t50% (weeks) 1.76 15.53 
f1 difference factor 54.4 
f2 similarity factor 24.2 
2.1.5. Antibacterial Efficacy Test 
Drug loaded PLA composite films were introduced to a 50 mL subculture of S. aureus in the 
beginning and also in time-delay of 90 min where the bacteria growth is at the middle of log phase. In 
both cases, the released gentamicin concentration was enough to control the growth of bacterial as 
shown in Figure 4a–c. It was also revealed that after 24 h there was no bacterial recovery seen. Most of 
the drug released in this period of time is surface associated drug molecules. Furthermore, samples 
from release study, after four weeks of release were also collected and subjected to efficacy testing. 
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This was important specifically when it is intended to be used as drug delivery system during 
prolonged periods.  
 
Figure 4. Antibacterial efficacy (a1) Controls compared with films loaded with gentamicin. 
All films were introduced immediately after inoculating media with bacteria; (b1) PLA 
films loaded with gentamicin after releasing gentamicin for four weeks in PBS (pH 7.4,  
37 °C and 100 rpm). Plain PLA films and media were used as positive and negative 
control, all films were introduced immediately after bacteria inoculation; (c1) Films loaded 
with gentamicin and PLAHApGM film after releasing gentamicin for four weeks. Plain 
PLA films and media were used as positive and negative control; all films were introduced 
immediately after bacteria inoculation. a2, b2, and c2 are post-bacterial growth level up to  
24 h of respective experiment. Error bars are mean standard deviation (SD) of two 
biological and technical replicates of the experiments conducted in different days. 
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2.1.6. Morphology of Film Composites in Release Study 
The morphologies of the films were investigated by SEM. For extended drug controlled release 
systems, degradation of polymeric matrix and the additional particulate matter (microspheres) control 
the release of drug. Drug release rate and release time is highly influenced by degradation kinetics of 
the degradable polymer which means the slower the degradation the longer the release time. Figure 5 
represents the morphology comparison of films loaded with gentamicin in release study after 1st and 
3rd weeks to zero time. 
The morphology of PLAHAp, gentamicin loaded PLA and PLAHAp thin film composites show the 
loaded particles existed in agglomerate forms within PLA matrix with an average size of 100 nm to  
1.5 μm for PLAGM and PLAHAp and 200 nm to 1 μm for PLAHApGM (Figure 5-week 0). However 
the distribution of drug and HAp drug loaded particles within PLA matrix seems to be good. The 
morphology also suggests that PLAGM sample has more gentamicin protruding close to the polymer 
surfaces compared to PLAHApGM which is inconsistence with drug encapsulation efficiency data. It 
also explains the differences in hydrophilicity between gentamicin and hydroxyapatite, the factor that 
influences interaction between them and PLA matrix. PLA, being hydrophobic should interact more 
with relatively more hydrophobic materials. 
 
Figure 5. SEM pictures of PLAGM, PLAHApGM and PLAHAp composites revealing the 
degraded morphology after 1st and 3rd weeks in PBS solution. 
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2.1.7. Statistical Analysis-Multivariate Approach (MANOVA) 
In order to improve understanding of the drug dissolution we analysed release data using 
multivariate approach statistical method. The idea is to compare drug release from different PLA thin 
film composites where the release is measured at several points over time. The assumptions were 
sampling time were equally spaced, release were normally distributed and data were complete with no 
missing observations. Statistical software, SPSS 21.0 for Windows was employed. Multivariate tests 
were conducted on Pillai’s Trace, Wilks’ Lambda Hotelling’s Trace and Roy’s Largest Root. The 
results show that release differences between PLAGM and PLAHApGM were very significant with  
** p ≤ 0.01 while the effect of time on their release was highly significant with *** p ≤ 0.001. 
2.2. Discussion  
The release of gentamicin from these devices seem to follow semi-empirical equation describe by 
Korsmeyer-Peppas model. Nevertheless, the ‘n’ coefficient obtained for PLAGM and PLAHApGM 
indicate that somehow a number of different mechanisms might control release. Thus, the release of 
gentamicin contained from PLA matrix seems to be mainly controlled by diffusion whereas for 
PLAHApGM is possibly mixture of diffusion, super case II mechanism and other mechanisms of 
transport which control drug release.  
It should be added that the analysis shows that the diffusion mechanism is observed for the PLAGM 
model (regression coefficients of models which use diffusion are good). However it is certain that at 
the end of the initial release, degradation of the polymeric network will “favour” the dissolution of the 
remainder of the drug. So, this phenomenon (diffusion and degradation) should occur at the end of the 
surface drug release (when dissolution of drug have created secondary porosity inside the polymeric 
network and resultant “fragility” of it) and/or depends to the dissolution rate, surface area, of the PLA 
film used. For this reason, we have to consider only the early part of the dissolution kinetic (just below 
60% drug released) and hence, in the case of PLAGM, the release can be assumed to proceed and 
mainly controlled by diffusional process. 
However, for the PLAHApGM composite model, the transport mechanisms are more complex: 
firstly, initial PLA matrix dissolution proceeds which exposes the HAp particles, consequently the 
surface drug from these particles are dissolved. Coralline HAp as a structure contains meso and 
nanopores and during the initial drug loading period which utilises vacuum, gentamicin penetrates the 
pores of the “HAp-coral” and coats its surfaces and its porous network. The gentamicin contained in 
these porosities will be released gradually.  
Following this initial PLA dissolution, HAp particle dissociation proceeds and further drug is 
released by diffusion. The process involves both diffusion and other transport mechanisms based on 
dissociation mode which accelerates the dissolution rate and hence influences the drug release rates. 
For this second mode we can assume that the release occurs in several stages:  
1. Release of the drug contained on the exposed composite surface.  
2. Diffusion of the drug through the polymeric network and slow release of some part of drug 
contained into the surfaces of the HAp particles which is less accessible. The polymer plays a 
role of barrier that allows a slower release.  
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3. Degradation/erosion and/or fragmentation of the polymeric composite which promotes 
accessibility to the “HAp-particle” porosity and facilitate release of gentamicin located inside 
porous network. 
4. Degradation of the HAp particles, which facilitates dissolution of Ca2+ and PO43− ions and 
exposure of further GM and dissolution by diffusion to the environment.  
Despite the fact that the mechanisms that govern the drug dissolution are not the same, diffusion 
might be the dominating mechanism in all of the mentioned processes. The release kinetic profiles of 
these biocomposites are characteristics of those of prolonged release drug delivery system. Dissolution 
profiles show slower gentamicin release from PLAHApGM highlighted by the t50%, 9 times higher 
than those of PLAGM. Moreover, the decrease of the rate of release is accompanied by the suppression 
of the early burst effect recorded for the PLAGM mixtures.  
PLAHApGM shows more controlled release and it displays the potential from extended release 
applications. The main reason for this pattern is the fact that drug entrapped within hydroxyapatite 
particles takes longer time to dissolve and diffuse into the solution compared to drug in polymeric 
matrix. The release data in Figure 4 show that about 40% of drug was released after two weeks from 
PLAGM device while 20% of drug was released after 3 weeks in PLAHApGM. After the drug close to 
the polymer composite surfaces is released, further release rate will depend on the polymer degradation 
rate. Figure 5 shows progressive degradation of both PLAGM and PLAHApGM films after 1 and 3 
weeks. Degradation of these films correlates with the drug release data with PLAGM showing faster 
degradation. Gentamicin being hydrophilic, PLAGM is suggested to be more hydrophilic and therefore 
more water interaction and resultant diffusion into the device and hence faster degradation and release 
rates. It is believed that after a period of time, degradation of PLA will be auto catalysed by the 
degraded acidic end groups. On the other hand, though PLAHAp film degraded progressively it 
seemed to be the slowest due to its relatively high hydrophobicity in the absence of drug.  
The presence of hydroxyapatite as bioactive particles within the matrix has an extra advantage as 
calcium and phosphate ion source which widens its applications in tissue engineering particularly in 
maxillofacial and orthopaedic applications.  
Clinical studies for systemic treatment of gentamicin suggest maximal antimicrobial activity is 
archived in once-daily gentamicin dosing of 10 times MIC. However, the studies also suggest that  
once-daily gentamicin treatment has similar toxicity to conventional multiple-daily administration. On 
the other hand, controlled release administration would significantly reduce toxicity and side effects of 
gentamicin in patients since only small amount of drug would be needed for local administration. 
In this current study a bacterial culture, S. aureus (SH1000), was used for antibacterial efficacy of 
gentamicin loaded PLA-HAp marine based composites. Since gentamicin lacks chromophores, it 
doesn’t absorb light in either UV or visible spectrum; therefore it didn’t interfere with optical density 
measurements, the method used to monitor bacterial growth. The release concentration from PLAGM 
and PLAHApGM for several weeks, indicated to have enough antimicrobial activity as shown in  
Figure 4b, c. The results, also indicated that PLA thin film and PLAHAp film composite without 
gentamicin showed no significant differences compared to the control, media without films. The 
prolonged ability to release drug from the films was tested by subjecting films that have released 
gentamicin in PBS for four weeks into antibacterial efficacy testing. The results suggested that, even 
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after releasing drugs for four weeks, films were able to still release enough gentamicin to prevent 
microbial activities, (Figure 4b,c). All films loaded with gentamicin exhibited significant ability to 
prevent bacterial growth even at high concentration of bacterial, first grown for 90 min (as shown in 
Figure 4c). The overall results indicate that no bacterial recovery observed in the culture with loaded 
films after 24 h. 
3. Experimental Section  
3.1. Materials 
Corals were obtained from the Great Barrier Reef, QLD Australia. Gentamicin, diammonium 
hydrogen phosphate (NH4)2HPO4, 98%), and sodium hypochlorite (NaClO) were obtained from Sigma 
Aldrich, Castle Hill, Australia). Bacteria Staphylococcus aureus (SH1000) derived from a sepsis 
isolate (NCTC8325) was used in all experiments.  
3.2. Methods 
3.2.1. Hydrothermal Conversion of Coral  
The coral samples were crushed in a mill and cleaned with 2% (v/v) NaClO, further ground within 
an aluminium oxide ball mill (46 rpm, 2 h), and then dried at 100 °C for 2 h before use. Hydrothermal 
conversion was carried out following Ben-Nissan procedures [4]. Briefly, coral powder was converted 
in a Parr reactor at 250 °C with the stoichiometric amount of diammonium hydrogen phosphate 
(NH4)2HPO4 to obtain hydroxyapatite (HAp). Hydrothermally converted coral powders were loaded 
with gentamicin using rotary evaporation technique then dried in vacuumed desiccators and then used 
for thin film composites. The required amount of gentamicin was dissolved in polished 18 MΩ 
(MilliQ, Millipore, Victoria, Australia) water and then mixed with HAp powder in a sonicator for five 
minutes. Then the mixture was allowed to dry in rotary evaporator at 60 °C under vacuum.  
3.2.2. Preparation of Film Composites  
PLA thin films and composites were prepared using a solvent casting technique described  
previously [10,15]. Briefly, PLA films were prepared by dissolving 0.50 g of polymer in 30 mL of 
chloroform (1.12% wt/v polymer concentration) under magnetic stirrer at room temperature until it 
was completely dissolved. Then the solution was transferred into petri dish and chloroform was 
allowed to evaporate under low vacuum (in a desiccator) for 48 h. The films were stored in desiccators 
for further analyses. The same procedure with 15 min ultrasonication was employed to prepare PLA 
with gentamicin (PLAGM) and PLA with converted coral and gentamycin (PLAHApGM) composites 
samples. Based on previous research [7,16] a range of gentamicin concentrations 5%–30% have been 
used. In any case minimum amount of drug should be considered for local release systems. A 
gentamicin concentration of 10% (w/w) was used in all experimental samples. 
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3.2.3. Minimal Inhibitory Concentration and Antimicrobial Efficacy  
Experimental samples used were designated as the following: Polylactic acid film as PLA: PLA 
film loaded with Gentamicin as PLAGM: PLA-hydroxyapatite composite film as PLAHAp: composite 
films of hydroxyapatite loaded with Gentamicin with PLA as PLAHApGM.  
According to CLSI, the Minimal Inhibitory Concentration (MIC) is the lowest concentration of an 
antimicrobial agent that prevents visible growth of a microorganism in an agar or broth dilution 
susceptibility test [15,16] Gentamicin MICs were determined using 96-well microtitre trays and broth 
microdilution techniques. Inoculum concentration of 5 × 106 CFU/mL was used in each well. MICs 
were determined in accordance with CLSI [17] guidelines. S. aureus ATCC 25923 strain was also used 
as the control S. aureus strain.  
An antimicrobial efficacy test was conducted in Tryptone Soya Broth (TSB). Inoculum density 
equivalent to 0.5 McFarland standards (1 × 108 CFU/mL) from overnight culture, with a 50 mL TSB 
sub-culture was used. PLA film composites loaded with gentamicin were either introduced in the 
beginning or after 90 min of bacterial growth in a dry incubator at 37 ± 0.1 °C, with shaking at  
220 rpm. The optical density of the culture was monitored by spectrophotometer at 595 nm from the 
experiment at time 0, which was immediately after introduction of gentamicin loaded PLA films, and 
every half an hour for the first 6 to 6.5 h. When OD reaches about 1, samples were diluted to 1:10 
before measurement. An additional time-point was obtained after 24 h to check for recovery. 
Replicates of all experiments were done in different days.  
3.2.4. Drug Release and Release Kinetics  
Drug release study of PLA thin film composites was conducted under SINK conditions in 
phosphate buffered saline (PBS) (0.1 M, Na3N 0.1%, pH 7.4) at 37 ± 0.1 °C) in a temperature 
controlled water bath shaker running at constant speed of 100 rpm. Each sampling time had its own 
independent samples under the same conditions and experiments were respectively individually terminated 
after sampling. All drug concentrations were determined by Cary 100 UV-Vis spectrophotometer 
(Agilent Technologies, Victoria, Australia, Cary Series UV-Vis Spectrophotometer) at the maximum 
absorbance of gentamicin-o-phthaldialdehyde complex, λmax = 332 nm, using procedures described  
in [7,18]. Ophthaldialdehyde reagent was prepared by dissolving 2.5 g ophthaldialdehyde in 62.5 mL 
methanol and adding with 3 mL 2-hydroxyethylmercaptan to 560 mL 0.04 M sodium borate in 
distilled water. 2 mL gentamicin solution, 2 mL o-phthaldialdehyde reagent were reacted for 45 min at 
room temperature. The absorbance, which corresponds to the gentamicin concentration, was then 
measured at 332 nm. A calibration curve was prepared for each set of measurements. Each prescribed 
sampling time had its own independent sample, therefore after sampling the respective experiment  
was terminated. 
To study the mechanisms involved in the release of gentamicin associated with these composites, 
the results were fitted to various mathematical models, characterizing diffusion, dissolution or/and 
erosion prevalence as well as mix of dissolution-diffusion rate processes. Zero order, 1st Order, 
Higuchi, Hixson-Crowell, Korsmeyer-Peppas and Reciprocal powered time have been tested. The 
mathematical modelling was carried out using GraphPad Prism software (GraphPad software Inc.,  
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La Jolla, CA, USA). The comparison of the release profiles between PLAGM and PLAHApGM was 
evaluated using t50% determined from the reciprocal powered time equation (i.e., the time necessary to 
release 50% of the drug substance) and the difference (f1) and similarity (f2) factors [13]. Two 
dissolution profiles are considered similar when f1 is not greater than 15 and f2 varies from 50 to 100.  
3.2.5. Morphology and Mechanical Properties  
The morphological analyses of PLA films and composites were performed in a Scanning Electron 
Microscope (SEM) (ZEISS Supra55VP, Zeiss, Germany). Samples were fixed by conductive adhesive 
tape on aluminium stubs and covered with carbon using a sputter coater. Images were taken at various 
magnifications at acceleration voltages of 20 kV. 
Mechanical characterization was performed according to the method described in [10]. Drug 
encapsulation efficiency (DEE) was determined by soaking 2 mg of samples in 2 mL of distilled water 
at 37 °C for 5 min and then measured the drug concentration of the solution using UV-Vis. This 
process dissolves drugs that are on the outer surface of the films. The efficiency was determined by the 
formula Equation (1). 
𝐷𝐸𝐸 =
𝑊𝑑𝑓 − 𝑊𝑑𝑠
𝑊𝑑𝑓
 (1) 
where, 𝑊𝑑𝑓 = Weight of drug in the film, 𝑊𝑑𝑠 = Weight of drug dissolved in solution. 
3.3. Statistical Analysis 
All data were expressed as mean and standard deviation. The release data were compared using 
Multivariate test on Pillai’s Trace, Wilks’ Lambda Hotelling’s Trace and Roy’s Largest Root and 
differences were considered significant when * p < 0.05, very significant ** p < 0.01 and highly 
significant *** p < 0.001, respectively. A p-value higher than 0.05 (p > 0.05) was taken as indicating 
no significant difference [19].  
4. Conclusions  
The study of PLA–calcium phosphate thin film composites reveals possible potential applications of 
these devices in the biomedical field as drug delivery systems. The flexibility of these devices allows 
them to conform into any desired clinical shape and size. Incorporation of hydroxyapatite in this drug 
from hydrothermally converted “marine” materials, has added advantages of controlled release, improved 
encapsulation efficiency, increases drug stability and maintenance of bioactivity and continuous supply 
of calcium and phosphate ions which can assist in bone regeneration and repair. The release profiles, 
exhibited a steady state release rate, with significant antimicrobial activity even at high concentration 
of bacteria. The systems also showed the potential for prolonged release of antibiotic.  
The developed systems have the potential to be applied to prevent microbial adhesion to medical 
implant surfaces due to its propensity to uptake and release antibiotics, as a consequence of its 
biodegradability potential. In addition, they can generally be used in surgery to prevent infections 
mainly caused by S. aureus. Characterization of in vivo release and bacterial adhesion on the film 
composites are being currently conducted. 
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